Systemic AL amyloidosis with disseminated intravascular coagulation associated with hyperfibrinolysis

International Journal of Hematology

Volumn 87, Issue 4, 2008, Pages 371-374

  Takahashi, Toru ^a   Suzukawa, Munehiro ^a,b   Akiyama, Masaru ^a   Hatao, Katsuhiro ^a   Nakamura, Yukinori ^b  

^a Tokuyama Central Hospital   (Japan)

^b YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AL amyloidosis; DIC; Nafamostat mesilate

Indexed keywords

GABEXATE MESILATE; MELPHALAN; NAFAMSTAT MESILATE; THALIDOMIDE;

ADULT; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BLEEDING; BLOOD CLOTTING; CASE REPORT; CLINICAL FEATURE; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FIBRINOLYSIS; HEMATURIA; HEPATOSPLENOMEGALY; HUMAN; MAINTENANCE THERAPY; PURPURA; RECURRENCE RISK; SYMPTOMATOLOGY; SYSTEMIC DISEASE; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

AMYLOIDOSIS; BIOPSY; BLOOD COAGULATION DISORDERS; FEMALE; FIBRINOLYSIS; HUMANS; MIDDLE AGED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 46149127099     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-008-0070-y     Document Type: Article

References (11)

1. Guidelines Working Group of UK Myeloma Forum; British Committee for Standards in Haematology, British Society for Haematology. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol. 2004;125:681-700.
2. Uprichard J, Perry DJ. Factor X deficiency. Blood Rev. 2002;16:97-110.
3. Liebman H, Chinowsky M, Valdin J, Kenoyer G, Feinstein D. Increased fibrinolysis and amyloidosis. Arch Intern Med. 1983;143:678-82.
4. Mumford AD, O'Donnell J, Gillmore JD, Manning RA, Hawkins PN, Laffan M. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol. 2000;110:454-60.
5. Gatel A, Cacoub P, Piette JC. AL amyloidosis combined with acquired factor V deficiency. Ann Intern Med. 1998;128:604-5.
6. Kyle RA, Greipp PR. Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc. 1983;58:665-83.
7. Perlin E, Brakman P, Berg HS, Kirchner PT, Moquin RB, Astrup T. Enhanced blood coagulation and fibrinolysis in a patient with primary amyloidosis. Thromb Haemost. 1971;26:9-14.
8. Liebman H, Carfagno M, Weitz I, et al. Excessive fibrinolysis in amyloidosis associated with elevated plasma single-chain urokinase. Am J Clin Pathol. 1992;98:534-41.
9. Ino Y, Suzuki K, Sato T, Iwaki M. Comparative studies of nafamostat mesilate and various serine protease inhibitors in vitro. Folia Pharmacol Japon. 1986;88:449-55.
10. Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood. 2007;110:3561-3.
11. Wechalekar AD, Goodman HJB, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007;109:457-64.